Compare AUROW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | CMMB |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Israel |
| Employees | 1900 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 9.1M |
| IPO Year | N/A | 2023 |
| Metric | AUROW | CMMB |
|---|---|---|
| Price | $0.29 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 44.0K | ★ 66.0K |
| Earning Date | 04-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $36.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.87 |
| 52 Week High | $1.99 | $3.86 |
| Indicator | AUROW | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 61.35 |
| Support Level | $0.26 | $1.52 |
| Resistance Level | $0.39 | $2.80 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 58.57 | 94.72 |
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.